drugset / Trial / NCT01020994

Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema

NCT01020994

Phase 2 Completed 150 enrolled Almirall, S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of the study is to determine the efficacy and safety of topical application of LAS41003 in comparison to LAS189962 and LAS189961 in the treatment of superinfected eczema.

Timeline

Start
2009-11
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LAS41003 Unknown Topical
Comparator Octenidine Small molecule Topical
Comparator Prednicarbate Small molecule Topical

Indications